Class Action Lawsuit Filed Against Beta Bionics (NASDAQ: BBNX)
Berger Montague PC has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX), alleging that the company and its officers misled investors regarding issues with their iLet Bionic Pancreas insulin pump during the period from July 30, 2025 to February 24, 2026. The lawsuit claims Beta Bionics downplayed concerns raised by an FDA inspection of its manufacturing facility, which reportedly included serious quality management and safety issues with their product. According to the complaint, investors were assured that the FDA's observations pertained only to customer complaints handling rather than device safety or efficacy. However, it is alleged that Beta Bionics failed to disclose critical findings related to malfunction investigations and risk analysis for its insulin pump. The revelation of these issues led to a decline in stock price and investor losses. The deadline for investors seeking lead plaintiff status is November 3, 2026. Class members who do not apply can still participate in any potential recovery without taking action before this date.
Tickers: $BBNX
Topics: FDA inspection lawsuit medical device safety stock price decline